BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31784210)

  • 1. A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine.
    Marangon E; Buzzo M; Posocco B; Gagno S; Zanchetta M; Iacuzzi V; Poetto AS; Guardascione M; Giodini L; Toffoli G
    J Pharm Biomed Anal; 2020 Feb; 179():112949. PubMed ID: 31784210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine.
    Posocco B; Buzzo M; Giodini L; Crotti S; D'Aronco S; Traldi P; Agostini M; Marangon E; Toffoli G
    J Pharm Biomed Anal; 2018 Oct; 160():360-367. PubMed ID: 30119000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Optimized LC-MS/MS Method for Quantification of Sunitinib and N -Desethyl Sunitinib in Human Plasma and Its Application for Therapeutic Drug Monitoring.
    Li Q; Tang T; Zhang M; Li L; Chen W
    Ther Drug Monit; 2023 Dec; 45(6):817-822. PubMed ID: 37074815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
    Rais R; Zhao M; He P; Xu L; Deeken JF; Rudek MA
    Biomed Chromatogr; 2012 Nov; 26(11):1315-24. PubMed ID: 22259028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.
    Rodamer M; Elsinghorst PW; Kinzig M; Gütschow M; Sörgel F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):695-706. PubMed ID: 21367676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.
    Lankheet NA; Steeghs N; Rosing H; Schellens JH; Beijnen JH; Huitema AD
    Ther Drug Monit; 2013 Apr; 35(2):168-76. PubMed ID: 23503442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
    Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
    de Bruijn P; Sleijfer S; Lam MH; Mathijssen RH; Wiemer EA; Loos WJ
    J Pharm Biomed Anal; 2010 Mar; 51(4):934-41. PubMed ID: 19931354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.
    Chen X; Wang Z; Liu M; Liao M; Wang X; Du H; Chen J; Yao M; Li Q
    Biomed Chromatogr; 2015 May; 29(5):679-88. PubMed ID: 25294592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
    Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
    J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
    Minkin P; Zhao M; Chen Z; Ouwerkerk J; Gelderblom H; Baker SD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):84-8. PubMed ID: 18823825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.
    Qiu F; Bian W; Li J; Ge Z
    Biomed Chromatogr; 2013 May; 27(5):615-21. PubMed ID: 23108983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of light sources on sunitinib measurements with photoisomerization.
    Matsunaga N; Kitahara T; Yamada M; Sato K; Kodama Y; Sasaki H
    Biomed Chromatogr; 2019 Feb; 33(2):e4407. PubMed ID: 30315654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
    Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
    Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An HPLC method for simultaneous quantification of sunitinib and its active metabolite, SU12662, using hydrophilic interaction chromatography principle.
    Gurjar M; Mehta P; Sharma J; Patil S; Kulkarni P; Patil A; Nookala M; Joshi A; Gota V
    Bioanalysis; 2020 Jan; 12(2):75-85. PubMed ID: 31928228
    [No Abstract]   [Full Text] [Related]  

  • 17. A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma.
    Jolibois J; Schmitt A; Royer B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Nov; 1132():121844. PubMed ID: 31678788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a simultaneous quantification method of imatinib and sunitinib and their main metabolites and its application in patients with gastrointestinal stromal tumor.
    Chen H; Lyu J; Gong Z; Han Y; Tao K; Zhou H
    Biomed Chromatogr; 2024 Mar; 38(3):e5804. PubMed ID: 38152034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Takasaki S; Tanaka M; Kikuchi M; Maekawa M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
    Biomed Chromatogr; 2018 Jun; 32(6):e4184. PubMed ID: 29283445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6α-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study.
    Posocco B; Buzzo M; Follegot A; Giodini L; Sorio R; Marangon E; Toffoli G
    PLoS One; 2018; 13(2):e0193500. PubMed ID: 29474420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.